Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation
Authors:
Open Access
- 25 November 2005
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 58 (12) , 1299-1304
Abstract
Aims: To evaluate the expression of common biological markers and the epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation (DCMDs). Materials/methods: Thirty DCMDs were clinicopathologically and immunohistochemically analysed and compared with 36 control cases of high grade conventional invasive ductal carcinoma (IDC). Results: EGFR, HER2/neu, oestrogen receptor, progesterone receptor, and p53 expression was seen in 21, one, three, four, and 20 of the 30 DCMDs, compared with eight, nine, 18, 17, and five of the 36 conventional IDCs (p < 0.05), respectively. In 16 of the 30 DCMDs, metastases were found in the brain, lung, bone, and liver, within a maximum of 47 months (mean, 13.9) after initial surgery, whereas only four of the 36 conventional IDCs metastasised to the lung and bone within a maximum of 27 months (mean, 18.0) after initial surgery (p = 0.0001). There was a significant difference in disease free survival between DCMD and conventional IDC (p = 0.001). EGFR was frequently overexpressed in DCMD compared with conventional IDC, whereas the expression of HER2/neu and hormone receptors was lower in DCMD. Fluorescent in situ hybridisation revealed that the mean EGFR to chromosome 7 centromere (CEP7) ratio of the 24 DCMD cases available for evaluation was 1.03, and EGFR gene amplification was not detected in the 21 DCMD cases with EGFR overexpression. Conclusion: Immunohistochemistry for myoepithelial markers and EGFR is useful for the accurate diagnosis and molecular target treatment of high grade DCMD.Keywords
This publication has 31 references indexed in Scilit:
- Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinomaLaboratory Investigation, 2004
- β‐Catenin and p53 analyses of a breast carcinoma tissue microarrayCancer, 2004
- Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer studyThe Journal of Pathology, 2004
- Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancerBreast Cancer Research, 2003
- Therapeutic Potential of Tyrosine Kinase Inhibitors in Breast CancerCancer Investigation, 2003
- The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the BreastLaboratory Investigation, 2002
- Medullary breast carcinoma vs. poorly differentiated ductal carcinoma: an immunohistochemical study with keratin 19 and oestrogen receptor stainingHistopathology, 1996
- Expression of p53 protein in infiltrating and in‐situ breast carcinomasThe Journal of Pathology, 1991
- Metaplastic carcinomas of the breast. I. Matrix-producing carcinomaHuman Pathology, 1989
- Metaplastic Carcinoma of the Breast : A Clinicopathologic Study of 29 PatientsAmerican Journal of Surgical Pathology, 1987